| scholarly article | Q13442814 |
| P356 | DOI | 10.2337/DIACARE.23.5.644 |
| P698 | PubMed publication ID | 10834424 |
| P2093 | author name string | L Heinemann | |
| T Heise | |||
| K Rave | |||
| M Sedlak | |||
| B Hompesch | |||
| R Linkeschova | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | placebo | Q269829 |
| insulin glargine | Q417317 | ||
| NPH insulin | Q1929845 | ||
| P304 | page(s) | 644-649 | |
| P577 | publication date | 2000-05-01 | |
| P1433 | published in | Diabetes Care | Q5270111 |
| P1476 | title | Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo | |
| P478 | volume | 23 |
| Q51819354 | A Novel Approach to Preventing Diabetic Ketoacidosis in a Patient Treated With an Insulin Pump |
| Q55162068 | A Review of Basal-Bolus Therapy Using Insulin Glargine and Insulin Lispro in the Management of Diabetes Mellitus. |
| Q34565168 | A comparison of intermediate and long-acting insulins in people with type 2 diabetes starting insulin: an observational database study. |
| Q79722143 | A method to predict the metabolic effects of changes in insulin treatment in subgroups of a large population based patient cohort |
| Q46602351 | A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes |
| Q37404208 | A subcutaneous insulin pharmacokinetic model for computer simulation in a diabetes decision support role: model structure and parameter identification |
| Q41862671 | A subcutaneous insulin pharmacokinetic model for computer simulation in a diabetes decision support role: validation and simulation |
| Q35974970 | All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine |
| Q34906412 | An overview of insulin glargine |
| Q64969071 | Assessing glycemia in type 1 diabetic patients using a microdialysis system for continuous glucose monitoring. |
| Q38136581 | Basal insulin analogues in the management of diabetes mellitus: What progress have we made? |
| Q46449114 | Basal insulin glargine vs prandial insulin lispro in type 2 diabetes |
| Q36426817 | Basal supplementation of insulin lispro protamine suspension versus insulin glargine and detemir for type 2 diabetes: meta-analysis of randomized controlled trials |
| Q93273386 | Case Report: High-concentration Insulin Glargine Overdose Complicated by Hepatic Steatosis |
| Q36989694 | Clinical Effectiveness and Safety of Analog Glargine in Type 1 Diabetes: A Systematic Review and Meta-Analysis |
| Q45946807 | Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes. |
| Q46521667 | Comparison of time-action profiles of insulin glargine and NPH insulin in normal and diabetic dogs |
| Q38665753 | Controlled release of biologics for the treatment of type 2 diabetes |
| Q37011970 | Defining the role of insulin detemir in Basal insulin therapy |
| Q36374363 | Design of non-standard insulin analogs for the treatment of diabetes mellitus |
| Q40084842 | Does hypoglycaemia affect the improvement in QoL after the transition to insulin in people with type 2 diabetes? |
| Q33932753 | Dose-response effects of insulin glargine in type 2 diabetes |
| Q33804562 | Early pharmacokinetic and pharmacodynamic effects of mixing lispro with glargine insulin: results of glucose clamp studies in youth with type 1 diabetes |
| Q41887004 | Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function |
| Q55006964 | Effects of glargine insulin on glycemic control in patients with diabetes mellitus type II undergoing off-pump coronary artery bypass graft. |
| Q40391758 | Effects of new insulin analogues HMR1964 (insulin glulisine) and HMR1423 on insulin receptors |
| Q37468435 | Effects of switching from insulin glargine or detemir to insulin degludec in patients with type 1 diabetes mellitus |
| Q80442179 | Engineering predictability and protraction in a basal insulin analogue: the pharmacology of insulin detemir |
| Q88312314 | Equivalent Recombinant Human Insulin Preparations and their Place in Therapy |
| Q83857027 | Evaluation of artificial pancreas technology for continuous blood glucose monitoring in dogs |
| Q41973961 | Evaluation of glucose response to 3 types of insulin using a continuous glucose monitoring system in healthy alpacas. |
| Q37893971 | Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs |
| Q33828255 | Glucose supply and insulin demand dynamics of antidiabetic agents |
| Q89366452 | Glycemic Control in Hospitalized Patients with Diabetes Receiving Corticosteroids Using a Neutral Protamine Hagedorn Insulin Protocol: A Randomized Clinical Trial |
| Q51278671 | Glycemic control and safety in Chinese patients with type 2 diabetes mellitus who switched from premixed insulin to insulin glargine plus oral antidiabetics: a large, prospective, observational study. |
| Q34042148 | Health economic evaluations comparing insulin glargine with NPH insulin in patients with type 1 diabetes: a systematic review |
| Q36359175 | How to achieve a predictable basal insulin? |
| Q35690608 | Hypoglycemia as a barrier to glycemic control |
| Q33863413 | Identifying and meeting the challenges of insulin therapy in type 2 diabetes |
| Q37087031 | Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study |
| Q37404176 | In silico simulation of long-term type 1 diabetes glycemic control treatment outcomes |
| Q42611726 | Insulin Detemir Is Characterized by a Consistent Pharmacokinetic Profile Across Age-Groups in Children, Adolescents, and Adults With Type 1 Diabetes |
| Q37153705 | Insulin analog preparations and their use in children and adolescents with type 1 diabetes mellitus |
| Q35988978 | Insulin analogs for the treatment of diabetes mellitus: therapeutic applications of protein engineering. |
| Q36947990 | Insulin analogs: impact on treatment success, satisfaction, quality of life, and adherence |
| Q34580951 | Insulin analogues: have they changed insulin treatment and improved glycaemic control? |
| Q36012958 | Insulin detemir in the treatment of type 1 and type 2 diabetes |
| Q24235596 | Insulin detemir versus insulin glargine for type 2 diabetes mellitus |
| Q74301094 | Insulin glargine |
| Q34507672 | Insulin glargine |
| Q33884391 | Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus |
| Q28074690 | Insulin glargine 300 U/mL in the management of diabetes: clinical utility and patient perspectives |
| Q34320632 | Insulin glargine and cancer risk in patients with diabetes: a meta-analysis |
| Q51322375 | Insulin glargine in pediatric patients with type 1 diabetes in Japan. |
| Q34449820 | Insulin glargine in the management of diabetes mellitus: an evidence-based assessment of its clinical efficacy and economic value. |
| Q36012923 | Insulin glargine in the treatment of type 1 and type 2 diabetes |
| Q34093019 | Insulin glargine: a review of its therapeutic use as a long-acting agent for the management of type 1 and 2 diabetes mellitus |
| Q35177665 | Insulin glargine: a systematic review of a long-acting insulin analogue |
| Q35194343 | Insulin glargine: an updated review of its use in the management of diabetes mellitus |
| Q34906391 | Insulin therapy in Europe |
| Q51313300 | Insulin therapy in children and adolescents with type 1 diabetes. |
| Q36920613 | Insulin therapy in diabetes mellitus: how can the currently available injectable insulins be most prudently and efficaciously utilised? |
| Q34451782 | Insulin therapy in type 2 diabetes |
| Q35799765 | Insulin treatment in children and adolescents. |
| Q37144833 | Insulin treatment in diabetic pregnancy |
| Q85159744 | Insulin treatment of Type 2 diabetes: a clinical perspective |
| Q88447761 | Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy for the Treatment of Type 2 Diabetes: Are Two Agents Better Than One? |
| Q34365284 | Insulins today and beyond |
| Q35134192 | Intensive diabetes management in pediatric patients |
| Q24241828 | Intermediate acting versus long acting insulin for type 1 diabetes mellitus |
| Q42730182 | International Forum for the Advancement of Diabetes Research and Care, April 29-30, 2011, Athens, Greece |
| Q41558812 | Investigation of the Physico-Chemical Properties that Enable Co-Formulation of Basal Insulin Degludec with Fast-Acting Insulin Aspart |
| Q49899858 | LY2963016 Insulin Glargine and Insulin Glargine (Lantus) Produce Comparable Pharmacokinetics and Pharmacodynamics at Two Dose Levels |
| Q47344047 | Light Control of Protein Solubility Through Isoelectric Point Modulation. |
| Q61807531 | Lilly Insulin Glargine Versus Lantus in Insulin-Naïve and Insulin-Treated Adults with Type 2 Diabetes: A Randomized, Controlled Trial (ELEMENT 5) |
| Q92233754 | Lilly Insulin Glargine Versus Lantus® in Type 2 Diabetes Mellitus Patients: India and East Asia Subpopulation Analyses of the ELEMENT 5 Study |
| Q24244721 | Long acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus |
| Q36515474 | Long-acting basal insulin analogs: latest developments and clinical usefulness |
| Q24245192 | Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus |
| Q34295534 | Management of type 2 diabetes. Evolving strategies for treatment |
| Q79865927 | Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada |
| Q33869943 | Nausea and vomiting due to insulin glargine in patient with type 1 diabetes mellitus |
| Q35087356 | New aspects of insulin therapy in type 1 and type 2 diabetes |
| Q37242616 | New insulin analogues and routes of delivery: pharmacodynamic and clinical considerations |
| Q35840625 | New strategies for basal insulin treatment in type 2 diabetes mellitus |
| Q35134210 | New technologies and therapeutic approaches for the management of pediatric diabetes |
| Q34934934 | Novel insulins: expanding options in diabetes management |
| Q45946980 | Omitting breakfast and lunch after injection of different long-acting insulin preparations at bedtime: a prospective study in patients with type 2 diabetes. |
| Q46675368 | Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial |
| Q44313142 | Optimizing Inpatient Glycemic Control with Basal-Bolus Insulin Therapy |
| Q34377857 | Orally active insulin mimics: where do we stand now? |
| Q34906433 | Patient perceptions of diabetes and diabetes therapy: assessing quality of life |
| Q38734496 | Perioperative Glycemic Management of Patients Undergoing Bariatric Surgery |
| Q44627220 | Pharmacokinetic and pharmacodynamic properties of insulin aspart and human insulin |
| Q36554243 | Plasma insulin profiles after subcutaneous injection: how close can we get to physiology in people with diabetes? |
| Q26865976 | Postprandial hyperglycemia and endothelial function in type 2 diabetes: focus on mitiglinide |
| Q37670097 | Practical Focus on American Diabetes Association/European Association for the Study of Diabetes Consensus Algorithm in Patients with Type 2 Diabetes Mellitus: Timely Insulin Initiation and Titration (Iran-AFECT). |
| Q36898852 | Refining basal insulin therapy: what have we learned in the age of analogues? |
| Q38301238 | Safety considerations with pharmacological treatment of gestational diabetes mellitus |
| Q33618721 | Standard and Novel Treatment Options for Metabolic Syndrome and Diabetes Mellitus |
| Q89415279 | Switching From Pre-mixed Insulin to Regimens with Insulin Glargine in Type 2 Diabetes: A Prospective, Observational Study of Data From Adriatic Countries |
| Q37107135 | Switching from premixed insulin to glargine-based insulin regimen improves glycaemic control in patients with type 1 or type 2 diabetes: a retrospective primary-care-based analysis |
| Q57599459 | The Mechanism of Protraction of Insulin Detemir, a Long-Acting, Acylated Analog of Human Insulin |
| Q35841209 | The alteration of aspart insulin pharmacodynamics when mixed with detemir insulin |
| Q26999454 | The evolution of insulin glargine and its continuing contribution to diabetes care |
| Q46452341 | The interpretation of glucose clamp studies of long-acting insulin analogues: from physiology to marketing and back. |
| Q38618376 | The past, present, and future of basal insulins |
| Q57412611 | Therapy of Type 1 Diabetes Mellitus |
| Q44606779 | Time-action profile of the long-acting insulin analogue insulin glargine in comparison to NPH insulin in Japanese volunteers. |
| Q57281197 | Time-action profiles of insulin degludec in healthy dogs and its effects on glycemic control in diabetic dogs |
| Q35694576 | Treatment satisfaction and quality-of-life between type 2 diabetes patients initiating long- vs. intermediate-acting basal insulin therapy in combination with oral hypoglycemic agents--a randomized, prospective, crossover, open clinical trial |
| Q35115119 | Two-way crossover comparison of insulin glargine and insulin detemir in basal-bolus therapy using continuous glucose monitoring |
| Q33602161 | U-500 regular insulin: clinical experience and pharmacokinetics in obese, severely insulin-resistant type 2 diabetic patients |
| Q24194881 | Ultra-long acting insulin versus long-acting insulin for type 1 diabetes mellitus |
| Q94398608 | Ultra‐long acting insulin versus long‐acting insulin for type 1 diabetes mellitus |
| Q28073342 | Update on the treatment of type 2 diabetes mellitus |
| Q90292340 | Use of Insulin Glargine 100 U/mL for the Treatment of Type 2 Diabetes Mellitus in East Asians: A Review |
Search more.